trending Market Intelligence /marketintelligence/en/news-insights/trending/ohA1DN7nZ5ABr2plBqFLlg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Avadel's injection for neonatal nutrition approved by US FDA

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Avadel's injection for neonatal nutrition approved by US FDA

Avadel Pharmaceuticals PLC's Nouress, an injection that provides nutrition to neonatal patients, has been approved by the U.S. Food and Drug Administration.

Nouress is a cysteine hydrochloride injection for neonatal patients that require total parenteral nutrition, a feeding system that delivers liquid nutrients like carbohydrates, proteins and fats intravenously, according to the Mayo Clinic.

Dublin-based Avadel, a pharmaceutical company focused on treating narcolepsy, also said in a Dec. 16 press release that the U.S. Patent and Trademark Office has issued a patent covering the Nouress product. The patent is set to expire in March 2039. The company has other U.S. patent applications pending for Nouress.

Avadel said the U.S. launch date for Nouress is still being decided. A similar product manufactured by Exela Pharma Sciences LLC called ELCYS was approved by the FDA in May, with an immediate launch.

Shares of Avadel were down 12.22% to $6.32 as of 12:07 p.m. ET on Dec. 16.